PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Plexus Ventures, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Pierre Fabre Medicament and Zambon S.p.A. Sign Commercial Agreement - Pierre Fabre Medicament and Zambon S.p.A. sign commercial agreement in Germany. Plexus Ventures, LLC represented Pierre Fabre in transaction
Pierre Fabre Medicament and Zambon S.p.A. Sign Commercial Agreement

 

NewswireToday - /newswire/ - Philadelphia, PA, United States, 2007/02/20 - Pierre Fabre Medicament and Zambon S.p.A. sign commercial agreement in Germany. Plexus Ventures, LLC represented Pierre Fabre in transaction.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Plexus Ventures, LLC, a global pharmaceutical business development firm, announced today the successful execution of an agreement between Pierre Fabre Medicament of France and Zambon S.p.A. of Italy. The deal, signed February 15, 2007, gives Pierre Fabre commercial rights for Zambon’s product portfolio in Germany.

The strategic partnership involves multiple products, including Panotile Cipro (anti-infective), Fluimicil (mucolytic), Monuril and Lorafem (antibiotics). In addition, Pierre Fabre will absorb Zambon’s specialist medical sales force in Germany to provide complete coverage of top physicians and pharmacists thus strengthening Pierre Fabre’s network in the country.

Pierre Fabre Medicament retained Plexus Ventures to assist with the company’s in-licensing and acquisition campaign in Germany. After careful evaluation of the client’s needs as well as a thorough assessment of the market, Plexus Ventures contacted more than 50 companies on behalf of Pierre Fabre and was involved in all aspects of the partnering process, from initial contacts through Due Diligence and final negotiations. The Plexus Ventures team was led by Mr. Pino Modica, Managing Partner, and success of the project was due in large part to the knowledge of the local marketplace brought by Senior Consultants Mr. Klaus Welzel in Frankfurt and Mr. Valerio Zoja in Milan.

"One of the main advantages Plexus Ventures brings to our clients is our strong international presence and extensive contacts within the most important markets in the Pharmaceutical industry," noted Pino Modica. "In this case, we were able to tap into our network of contacts within the industry to bring new opportunities to the table which were not publicly known. We are proud we were able to meet our client’s needs by finding an ideal partner and a deal structure which will benefit both parties in the long run."

Mr. Alain Benoit, Vice President of Corporate Licensing and Acquisitions for Pierre Fabre commented, "We knew that this was a difficult task and we are glad Plexus Ventures was able to meet the challenge and help us to achieve this important strategic objective of consolidating our presence in the German market."

Plexus Ventures (plexusventures.com), founded in 1990, provides strategic advice, business development and alliance management services to clients in the pharmaceutical, biotechnology and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Frankfurt, London, Los Angeles, Milan, Philadelphia, Tokyo and Warsaw, Plexus Ventures possesses the capabilities to effectively serve clients in the United States, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Plexus Ventures, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Pierre Fabre Medicament and Zambon S.p.A. Sign Commercial Agreement

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Mary Alice Strong - PlexusVentures.com 
310-315-7106 mas[.]plexusventures.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Plexus Ventures, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Plexus Ventures, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  Al Rowaad Advocates & Legal Consultants





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)